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significance for any size category. Mean transit time
through the entire gastrointestinal tract, from ingestion
to excretion, was shorter with the Study regimen while
mean colonic transit times were similar for both study
groups.
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Core tip: Current bowel preparation boost agents for
colon capsule endoscopy have associated risks and
contraindications. This paper describes a new boost
agent comprised of two very low dose hyperosmotic
agents, oral sodium sulfate and diatrizoate solution,
which appears to be an acceptable alternative regimen
for colon capsule endoscopy.

Abstract
AIM
To assess the cleansing efficacy and safety of a new
Colon capsule endoscopy (CCE) bowel preparation
regimen.

Kastenberg D, Burch WC, Romeo DP, Kashyap PK, Pound DC,
Papageorgiou N, Fernández-Urien Sainz I, Sokach CE, Rex DK.
Multicenter, randomized study to optimize bowel preparation
for colon capsule endoscopy. World J Gastroenterol 2017;
23(48): 8615-8625 Available from: URL: http://www.wjgnet.
com/1007-9327/full/v23/i48/8615.htm DOI: http://dx.doi.
org/10.3748/wjg.v23.i48.8615

METHODS
This was a multicenter, prospective, randomized,
controlled study comparing two CCE regimens. Subjects
were asymptomatic and average risk for colorectal cancer.
®
The second generation CCE system (PillCam COLON
2; Medtronic, Yoqneam, Israel) was utilized. Preparation
st
nd
regimens differed in the 1 and 2 boosts with the
Study regimen using oral sulfate solution (89 mL) with
diatrizoate meglumine and diatrizoate sodium solution
(“diatrizoate solution”) (boost 1 = 60 ml, boost 2 =
30 ml) and the Control regimen oral sulfate solution
(89 mL) alone. The primary outcome was overall
and segmental colon cleansing. Secondary outcomes
included safety, polyp detection, colonic transit, CCE
completion and capsule excretion ≤ 12 h.

INTRODUCTION
Colon capsule endoscopy (CCE) is a non-invasive
procedure which effectively visualizes the entire colon.
While CCE technology has advanced, the preparation
regimen remains a challenge. Not only is a clean and
fluid filled colon requisite, but the capsule must reach
the hemorrhoidal plexus within its 12-h battery life.
Furthermore, the capsule must dwell for a sufficient
period of time within the colon as rapid transit (< 40
min) in combination with sub-optimal cleansing may
[1]
lower the sensitivity for detecting polyps .
The CCE preparation regimen before capsule
ingestion focuses on cleansing the colon, whereas postcapsule ingestion measures are aimed at propelling
the capsule through the gastrointestinal (GI) tract and
providing additional cleansing. A full dose purgative,
typically polyethylene glycol-electrolyte solution (PEGELS), is administered as a split dose prior to capsule
ingestion. After capsule ingestion, a pro-kinetic
medication - in the United States metoclopramide -

RESULTS
Both regimens had similar cleansing efficacy for the
whole colon (Adequate: Study = 75.9%, Control =
77.3%; p = 0.88) and individual segments. In the
Study group, CCE completion was superior (Study
= 90.9%, Control = 76.9%; p = 0.048) and colonic
transit was more often < 40 min (Study = 21.8%,
Control = 4%; p = 0.0073). More Study regimen
subjects experienced adverse events (Study = 19.4%,
Control = 3.4%; p = 0.0061), and this difference did
not appear related to diatrizoate solution. Adverse
events were primarily gastrointestinal in nature and
no serious adverse events related either to the bowel
preparation regimen or the capsule were observed.
There was a trend toward higher polyp detection with
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may be administered if the capsule does not exit the
stomach within an hour. Upon entering the duodenum,
and then typically 3 and 5 h later if the capsule has not
exited the colon, an agent (“boost”) is administered to
accelerate capsule transit and augment cleansing.
Generally the first and second boost consists of a
hyperosmotic agent and, to date, sodium phosphate
[2-10]
liquid (NaP) has most commonly been used
. How
ever, numerous contraindications to the use of NaP
[11,12]
makes it a non-viable option in the United States
.
As an alternative to NaP, a large prospective CCE
study used oral sulfate solution (OSS) for the first 177
[1]
ml (6 oz.) and second 89 ml (3 oz.) boost . While
overall bowel preparation adequacy was acceptable,
an unexpected limitation of this regimen was a higher
than expected rate of technically inadequate studies
due to the combination of rapid colonic transit and
inadequate colon cleansing.
Diatrizoate meglumine and diatrizoate sodium
solution (“diatrizoate solution”) is a hyperosmotic
agent used in radiologic imaging, and when orally
administered causes an influx of fluid into the GI
[13]
tract resulting in diarrhea . A small CCE study used
diatrizoate solution alone as a boost agent and found
high rates of adequate colon cleansing and CCE
completion, while rapid colonic transit (< 40 min) was
[14]
rare . A larger study combined diatrizoate solution
with NaP as a boost agent and observed adequate
colon cleansing in 83%, and CCE completion in 98%,
[15]
of subjects .
This study evaluated the efficacy and safety of
a new CCE preparation regimen that combines low
dose OSS with diatrizoate solution as a boost agent.
The study was conducted at six centers in the United
States.

within 12 h of ingestion, and safety. Colon cleansing
was assessed using a validated 4-point grading scale
of excellent, good, fair, and poor for individual colon
[16]
segments and for the overall colon . Adequate
cleansing was defined as a combination of good and
excellent.

Subjects

Subjects were asymptomatic and average risk for
colorectal cancer (CRC), and ranged in age from 50-75
years. Average risk was defined using the American
Gastroenterology Association Guidelines on Colorectal
[17]
Cancer Screening . Subjects did not have a personal
history of CRC or adenoma or inflammatory bowel
disease, a first degree family member with CRC under
age 60 or two or more first degree relatives with CRC
at any age, or a personal or family history of a genetic
syndrome high risk for CRC.
Furthermore, subjects were excluded if they had a
negative colon evaluation within 5 years (colonoscopy,
CTC, flexible sigmoidoscopy, barium enema, or stool
testing for blood and/or DNA); a history of GI bleeding,
heme positive stool, or iron deficiency; a contrain
dication to capsule technology including dysphagia
or any swallowing disorder, a cardiac pacemaker or
implanted electromedical device, anticipation of
magnetic resonance imaging within 7 d of capsule
ingestion, or increased risk for capsule retention
including a suspected or known GI motility disorder,
bowel obstruction, stricture or fistula; a history of
renal disease; an allergy or contraindication to any
component of the study regimens; pregnancy or active
breast feeding; participation in another investigational
study within 30 d that may interfere with the subject’s
safety or ability to participate in this study; a member
of a vulnerable population (prisoner, intellectually
challenged, etc.); or a severe medical condition such
that participation is not appropriate due to increased
risk, lack of benefit of screening, or survival anticipated
to be less than 6 mo.

MATERIALS AND METHODS
This was a multicenter, prospective, randomized,
controlled study designed to assess the superiority
of a new colon cleansing regimen for CCE. Six
centers (2 academic) participated, and subjects were
enrolled between 5/18/15 and 9/23/15. Each center
obtained IRB approval prior to study initiation, and
this protocol was registered with clinicaltrials.gov (ID#
NCT02481219).
®
The second generation CCE system (PillCam
COLON 2; Medtronic, Yoqneam, Israel), was used in this
study. This consists of an ingestible capsule, sensors
attached to the abdominal wall that receive capsule
signals, a data recorder, and software (RAPID, version
8.3) enabling image display and creation of reports.
The primary outcome was overall and segmental
colon cleansing. Secondary outcomes included polyp
detection (≥ 6 mm, ≥ 10 mm, and total), colonic
transit time, CCE completion (defined as visualization
of the hemorrhoidal plexus), excretion of capsule

WJG|www.wjgnet.com

Study procedure

Subjects underwent a screening visit to assess
eligibility. Demographic information as well as medical
and surgical history was obtained, and an assessment
of pregnancy potential was performed. Subjects of
childbearing potential underwent a urine pregnancy
test at the time of screening. During the screening
visit, if eligibility criteria were satisfied, informed
consent was obtained and subsequently subjects were
randomized in a 1:1 ratio to receive the study bowel
preparation regimen (Study) or the comparator control
bowel preparation regimen (Control) (see bowel
preparation regimen section below and Table 1). This
study utilized randomization blocks using a standard
envelope procedure. The CCE was performed within 45
days of the screening visit.
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Table 1 Bowel preparation regimens
Time

Study regimen

2 d prior

≥ 2400 mL (10 glasses) of liquid during the day; 4 senna tablets

1 d prior

at bedtime
Clear liquid diet all day; 2 L sulfate-free PEG-ELS1 at about 7-9
pm (one 237 mL-296 mL cup (8-10 oz. cup) every 10-15 min)

Day of capsule procedure
45-75 min prior to capsule ingestion
1 h after capsule ingestion
1st boost: After capsule entry into small bowel2
2nd boost: 3 h after 1st boost, only if capsule not excreted
3rd boost: 2 h after 2nd boost, only if capsule not excreted
2 h after 3rd boost, or after capsule passes (whichever occurs first)

2 L sulfate-free PEG-ELS
Optional prokinetics (only if capsule in stomach > 1 h): 10 mg
metoclopramide or 250 mg erythromycin
89 mL (3 oz) OSS plus 60 mL diatrizoate solution1
89 mL (3 oz) OSS plus 30 mL diatrizoate solution1
10 mg bisacodyl suppository
Standard full meal

Control regimen

89 mL (3 oz.) OSS
89 mL (3 oz.) OSS

1

Diatrizoate solution = diatrizoate meglumine and diatrizoate sodium solution; 2Clear liquids permitted after ingestion of 1st boost, PEG-ELS: Polyethylene
glycol-electrolyte solution; OSS: Oral sulfate solution.

The CCE videos were read remotely by two
readers who had extensive experience reading CCE
studies and were unassociated with any study site.
Video assignment to centralized readers utilized a 1:1
randomization stratified by bowel preparation group
to minimize bias using MDT data manager (Medtronic,
Mansfield, MA, United States). Videos were read within
3 wk of CCE completion, and no more than 5 videos
per week were read by a single reader.
Readers used the aforementioned four-point scale
to grade cleansing for 5 colon segments - cecum,
right colon, transverse colon, left colon, and rectum.
Additionally, readers provided an overall cleansing
grade for the entire colon.
For each polyp, the location and size, as determined
by the longest dimension using a software measuring
tool, was recorded. The time for the capsule to reach
the cecum, hepatic and splenic flexures, and exit the
rectum was also measured using software. The cecum
and last rectum image was identified by the reader,
and then the other colon landmarks were identified by
either the software or the reader.
The completed report was provided to the primary
investigator at each enrollment site within 3 months of
the capsule procedure. Follow-up of capsule findings
was left to the discretion of the primary investigator at
each site.

boost once the capsule entered the duodenum, and
nd
a 2 boost 3 h later if the capsule had not been
excreted. Study and Control regimens differed in the
st
composition of these boosts. For the 1 boost, the
Study regimen used 89 ml (3 oz.) of OSS (SUPREP
® Braintree Laboratories Inc., Braintree, MA) diluted
to 237 ml (8 oz.) with water and 59 ml (2 oz.) of
®
diatrizoate solution (Gastrografin , Bracco Diagnostics
Inc., Monroe Township, NJ, United States) diluted to
nd
207 ml (7 oz.) with water, and for the 2 boost 89 ml
(3 oz.) of OSS diluted to 237 ml (8 oz.) with water
and 30 ml (1 oz.) of diatrizoate solution diluted to 89
st
nd
ml (3 oz.) with water. For both the 1 and 2 boosts,
the Control regimen used 89 ml (3 oz.) of OSS diluted
to 237 ml (8 oz.) with water. Subjects in both study
arms drank at least 946 ml (32 oz.) of water with the
first and second boosts.
nd
Two hours after the 2 boost, if the capsule had not
been excreted, subjects in both study arms received a
rd
3 boost consisting of a 10 mg bisacodyl suppository.
Diet was identical for subjects in both study arms.

Safety

Adverse events were recorded throughout the CCE
preparation regimen. Subjects were called 5-9 d
after completion of the capsule procedure to confirm
capsule excretion and record any additional adverse
events. Adverse events were classified as serious
or non-serious. Non-serious adverse events were
characterized and then classified as mild, moderate, or
severe.

Bowel preparation regimens

The Study and Control bowel preparation regimens are
summarized in Table 1. For both regimens, all subjects
took 4 senna tablets the evening of Day -2, and 2
L of sulfate-free PEG-ELS (NuLYTELY®, Braintree
Laboratories Inc., Braintree, MA, United States) the
night before the capsule procedure and again the next
morning with completion 45-75 min before capsule
ingestion. If the capsule remained in the stomach
more than 1 h, subjects in both study arms took
metoclopramide 10 mg or erythromycin 250 mg orally.
st
All subjects (Study and Control) received a 1

WJG|www.wjgnet.com

Comparison of study and control regimens with historic
comparators

Preparation adequacy, CCE completion, capsule transit
times, and polyp detection were compared between the
study and control regimens and similar regimens used
[1,15]
in two published CCE studies
.The Study regimen
[15]
was compared to Spada et al
as both used the
combination of diatrizoate solution and a hyperosmotic
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Table 2 Subject characteristics

Age (yr)
Gender (male:female)
BMI (mean)

st

Study regimen, n = 62

Control regimen, n = 59

P value

55.20
45:55
28.50

55.10
49:51
28.50

0.888
0.660
0.978

nd

purgative for the 1 and 2 boosts. However, instead
[15]
of OSS and diatrizoate solution, Spada et al . used
st
NaP in combination with diatrizoate solution [1 boost
= 40 ml (1.4 oz.) NaP and 50 ml (1.7 oz.) diatrizoate
nd
solution in 1 L (34 oz.) of water; 2 boost = 25 ml (0.8
oz.) NaP and 25 ml (0.8 oz.) diatrizoate solution in
0.5 L (17 oz.) of water].
The Control regimen was compared to a CCE
[1]
preparation regimen used by Rex et al . Both
regimens were similar except for the OSS dose used
st
for the 1 boost [Control = 89 mL (3 oz.) diluted to
237 mL (8 oz.) plus an additional 946 mL (32 oz.) of
[1]
water, Rex et al = 177 mL (6 oz.) diluted to 473 mL
(16 oz.) plus an additional 946 ml (32 oz.) of water].
Similar to the Study and Control regimens, both
[15]
[1]
Spada et al
and Rex et al administered 4 senna
tablets two days prior to CCE, split dose 4 L PEG-ELS
beginning the night prior to CCE, and a prokinetic
agent if the capsule remained in the stomach for more
than 1 h.

and for the entire colon.
Plan for interim analyses: Interim analyses were
planned after each group of 50 subjects until a
final enrollment of 500. Pre-specified criteria were
established for measures of performance and safety
that would allow discontinuation of the trial. These
included the following: (1) an increased prevalence (>
10%) of polyps (≥ 6 mm and ≥ 10 mm) in the Study
group; (2) an increased incidence of adequate (good/
excellent) cleansing (> 12%) for the whole colon in
the Study group; and (3) adverse events in fewer than
10% of subjects in the Control group.

RESULTS
Subject flow is summarized in Figure 1. There were
126 subjects screened and consented, 122 subjects
met eligibility criteria, and 121 ingested any of the
preparation and were included in the analyses for
subject characteristics and safety. After excluding 14
subjects for protocol deviations, 107 were included in
the analyses for colon cleansing and polyp detection
by colonic segment, CCE completion and transit times,
and comparisons between the Control regimen and
[1]
Rex et al . for colon cleansing by segment. Both study
groups were similar with regard to age, gender, and
body mass index (BMI) (Table 2).
After excluding 5 additional subjects with ≥ 1
unseen colon segment (cecum, ascending, or tran
sverse), 102 subjects were analyzed for overall colon
cleansing, polyp detection for the whole colon, and
comparisons between the Study regimen and Spada
[15]
[1]
et al
and the Control regimen and Rex et al for
overall cleansing of the colon. Five additional subjects
were excluded who had both inadequate (fair or poor)
overall colon cleansing and colonic transit < 40 min. The
[15]
exclusions for this final group matched Spada et al
[1]
and Rex et al to allow comparisons for polyp detection
for the whole colon.
The a priori criteria for early termination of this
study were met after the first group of 50 subjects.
Because enrollment was rapid, by the time the
analyses had been completed and the decision to halt
the study made, more than 100 subjects were enrolled
and the results are presented herein.

Statistical analysis

The statistical methods of this study were reviewed by
Mathilde Lourd, a biostatistician from Medtronic Inc.
Primary outcome: A sample size of 500 patients
would provide > 80% power to detect a difference
between the study groups for overall colon preparation
adequacy with a two-sided test at a significance
level of 0.05 (adequacy assumptions: 83% Study,
71% Control). Chi-square or Fisher’s exact test, as
appropriate, was performed to compare proportions
of good and excellent cleansing between the two
preparation regimens. Non-visualized colon segments
were not graded for cleansing and not included in the
colon segment preparation grading analysis.
Secondary outcomes: Chi-square or Fisher’s exact
tests were used for analyzing polyp detection (≥
6 mm, ≥ 10 mm, and any polyp) in total for the
whole colon and by colon segment, CCE completion
rate, adverse events in relation to administration
of diatrizoate solution, and colon capsule excretion
within 12 h of ingestion. Colon capsule completion
was defined as excretion of the capsule within 12 h
of ingestion and complete visualization of the colon.
t-tests for continuous variables were performed to
evaluate the difference between the two preparation
regimens for capsule transit time by colon segment
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Cleansing efficacy

For overall colon cleansing, there was no significant
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Table 3 Overall colon cleansing assessment
Overall cleansing assessment [95%CI]
Adequate1
Excellent
Good
Fair
Poor

Study regimen, n = 55

Control regimen, n = 52

P value

75.9 [62.4; 86.5]
16.7 [7.9; 29.3]
59.3 [45.0; 72.4]
24.1 [13.5; 37.6]
0.0 [0.0; 5.9]

77.3 [62.2; 88.5]
6.8 [1.4; 18.7]
70.5 [54.8; 83.2]
22.7 [11.5; 37.8]
0.0 [0.0; 6.6]

0.876
0.216
0.243
0.875
--

1

Includes both excellent and good cleansing.

Table 4 Polyp detection by size for the whole colon
Polyp size [95%CI]
≥ 6 mm
≥ 10 mm
Any polyp

Study regimen, n = 55

Control regimen, n = 52

P value

36.4 [23.8; 50.4]
14.6 [6.5; 26.7]
58.2 [44.1; 71.3]

21.3 [10.7; 35.7]
8.5 [2.4; 20.4]
46.8 [32.1; 61.9]

0.096
0.346
0.251

Table 5 Colon capsule endoscopy completion and transit times

CCE completion [95%CI]
CCE excretion ≤ 12 h [95%CI]
GI tract transit - Ingestion to excretion1, mean (SD) [95%CI]
Colonic transit time1, mean (SD) [95%CI]
Colonic Transit < 40 min [95%CI]

Study regimen, n = 55

Control regimen, n = 52

P value

90.9 [80.0; 97.0]
90.9 [80.0; 97.0]
5:54 (6:00) [4:18; 7:30]
2:12 (1:36) [1:48; 2:42]
21.8 [11.8; 35.0]

76.9 [63.2; 87.5]
80.4 [66.9; 90.2]
9:00 (11:48) [5:36; 12:24]
2:36 (1:30) [2:06; 3:06]
4.0 [0.5; 13.7]

0.0482
0.121
0.107
0.262
0.0072

1

All transit times measured as (h:min); 2Statistically significant. CCE: Colon capsule endoscopy.

difference between the Study and Control regimens
using the 4-point scale of excellent, good, fair or
poor (Table 3). Overall adequate cleansing (good and
excellent combined) of the whole colon was similar for
both study groups (Adequate: Study = 75.9%, Control
= 77.3%, p = 0.88). When the 4-point scale was used
to grade individual colon segments, in no segment was
there a significant difference between the Study and
Control regimens for any grade (Supplementary Tables
1-4).

transit time through the entire GI tract, from ingestion
to excretion, was shorter with the Study regimen while
mean colonic transit times were similar for both study
groups. Significantly more Study regimen subjects
experienced capsule transit through the colon in
less than 40 min (Study = 21.8%; Control = 4%, p
= 0.007). Five subjects (9%) in the Study regimen
arm had both inadequate colon cleansing and colonic
transit < 40 min.

Safety

Polyp detection

Adverse events occurred more often in subjects
receiving the Study regimen [Study = 12 (19.4%),
Control = 2 (3.4%); p = 0.0061], and these were
primarily related to bowel preparation [Study = 8
(12.9%), Control = 1 (1.7%); p = 0.0327] and were
gastrointestinal in nature (Table 6). The incidence of
adverse events in Study regimen subjects was similar
before and after administration of diatrizoate solution
(before diatrizoate solution = 9.7%, after diatrizoate
solution = 6.5%; p = 0.4142.) One serious adverse
event occurred with the Study regimen (sinusitis), and
this was judged unrelated to the preparation regimen
or the capsule procedure. All adverse events in the
Control regimen arm were graded as mild, and there
was a non-significant trend toward a higher level of
adverse event severity experienced by Study regimen

Table 4 summarizes overall polyp detection for both
study groups. There was a trend toward higher polyp
detection for the whole colon with the Study regimen,
although this was not statistically significant for any
size category. When evaluated by colon segment,
detection of polyps of all sizes (≥ 6 mm, ≥ 10 mm,
and any polyp) was not significantly different between
the Study and Control regimens (Supplementary
Tables 5-7).

Capsule colon endoscopy completion and transit

Colon capsule completion and transit times are
summarized in Table 5. Superior completion of the
CCE procedure was achieved with the Study regimen
(Study = 90.9%, Control = 76.9%; p = 0.048). Mean
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Screened subjects
n = 126

Consented subjects
n = 126

n = 4 subjects identified as screen failure
after obtaining informed consent

Randomized subjects
n = 122
Control

Study

n = 60

n = 62

n = 1 subject randomized but did not drink
preparation regimen or swallow capsule
1

A

n = 121
Study

Control

n = 62

n = 59

B

n = 14 subjects deviated from the
preparation regimen and/or colon capsule
procedure(s) as per protocol

2

n = 107
Study

Control

n = 55

n = 52
n = 5 subjects with one or more unseen segment(s)
in cecum/ascending/transverse
3

C

n = 102
Study

Control

n = 55

n = 47
n = 5 subjects with both inadequate (fair or poor)

D

cleansing level on overall colon cleansing and with
colonic transit time < 40 min

4

n = 97
Study

Control

n = 50

n = 47

Figure 1 Patient flow diagram. 1Group A received any of the CCE preparation regimen = Baseline subject characteristics, safety analysis, comparisons between
Control regimen and Rex et al[1] and between Study regimen and Spada et al[15] for colon capsule completion and transit times. 2Group B excluded subjects who
withdrew before capsule ingestion, had a protocol violation, or experienced technical failure of the capsule = Colon cleansing by segment, CCE completion, CCE
transit times, polyp detection by colon segment, comparisons between Control regimen and Rex et al[1] for colon cleansing by segment. 3Group C excluded subjects
listed above (B), and those with non-visualization of the cecum, right colon, or transverse colon = Colon cleansing for whole colon, polyp detection for the whole colon,
comparisons between the Control regimen and Rex et al[1] and between the Study regimen and Spada et al[15] for overall cleansing of the colon. 4Group D excluded
subjects listed above (B and C) and those with both inadequate overall colon cleansing and colonic transit time < 40 min = Comparisons between Control regimen and
Rex et al[1] and Study regimen and Spada et al[15] for whole colon polyp detection.
[1]

subjects (Table 6).

Control regimen: The Control and Rex et al
regimens had similar overall cleansing efficacy for
the whole colon and for individual colon segments.
However, the Control regimen had a significantly lower
[1]
rate of completion (Control = 77.6%, Rex et al =
89%; p = 0.041) and a longer mean colonic transit
[1]
time (Control = 2 h 48 min, Rex et al = 1 h 52
min; p < 0.001). Polyp detection was not significantly

Comparisons to historical groups

Study regimen: The Study regimen demonstrated
[15]
no significant difference as compared to Spada et al
for overall cleansing of whole colon, CCE completion,
capsule transit through the entire GI tract, and overall
polyp detection (Table 7).
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Table 6 Adverse events: Frequency and severity by subject
Adverse event
Subjects with ≥ 1, n (%) [95%CI]
Occurring in > 2% of subjects, n (%) [95%CI]
Headache
Nausea
Vomiting
Maximum AE severity1, n (%) [95%CI]
Mild
Moderate
Severe

Study regimen, n = 62

Control regimen, n = 59

P value

12 (19.4) [10.4; 31.4]

2 (3.4) [0.4; 11.7]

0.0062

2 (3.2) [0.4; 11.2]
4 (6.5) [1.8; 15.7]
2 (3.2) [0.2; 38.5]

1 (1.7) [0.0; 9.1]
2 (3.4) [0.4; 11.7]
0 (0) [0.0; 77.6]

6 (50) [21.1; 78.9]
5 (41.7) [15.2; 72.3]
1 (8.3) [0.2; 38.5]

2 (100) [22.4; 100.0]
0 (0) [0.0; 77.6]
0 (0) [0.0; 77.6]

0.308

1

Subjects were counted once according to maximum severity; 2nd Statistically significant.

Table 7 Comparisons between Study regimen and Spada et al
Parameter
Adequate preparation-whole colon (% [95%CI])
CCE completion (% [95%CI])
GI transit time2, mean (SD) [95%CI]
Polyp detection (% [95%CI])
≥ 6 mm
≥ 10 mm

[15]

: Bowel cleansing, capsule transit, and polyp detection
1

Study regimen

Spada et al (4)

75.9 [62.4; 86.5]
90.2 [79.8; 96.3]
6:00 (6:12) [4:24; 7:36]

78.0[64.0; 88.5]
96.0 [86.3; 99.5]
6:06 (4:48) [4:46; 7:26]

P value
0.820
0.291
0.925

36.0 [22.9; 50.8]
16.0 [7.2; 29.1]

25.0 [13.6; 39.6]
12.5 [4.7; 25.2]

0.233
0.619

1 st

1 boost = 40 mL sodium phosphate liquid (NaP) and 50 mL diatrizoate solution; 2boost = 25 mL NaP and 25 mL diatrizoate solution; 2All transit times
measured as (hour: minutes). CCE: Colon capsule endoscopy.

Table 8 Comparisons between Control regimen and Rex et al
Parameter
Adequate preparation–whole colon (% [95%CI])
CCE completion (% [95%CI])
GI transit time2, mean (SD) [95%CI]
Polyp detection (% [95%CI])
≥ 6 mm
≥ 10 mm

[1]

: Bowel cleansing, capsule completion and transit, and polyp detection
1

Control regimen

Rex et al (7)

77.3 [62.2; 88.5]
77.6 [64.7; 87.5]
2:48(1:36) [2:18; 3:18]

71.4 [68.1; 74.5]
89.0 [86.8; 91.0]
1:52 (1:40) [1:45; 1:59]

P value
0.369
0.0413
< 0.0013

21.3 [10.7; 35.7]
8.5 [2.4; 20.4]

31.5 [28.1; 35.1]
11.4 [9.1; 14.0]

0.100
0.810

1

Used 6 ounces sulfate solution for 1st and 2nd boosts; 2All transit times measured as (hour: minutes); 3Statistically significant. CCE: Colon capsule endoscopy.

different between the two regimens, but there was a
trend toward higher detection for polyps ≥ 6 mm with
[1]
the Rex et al bowel preparation regimen (Table 8).

adverse events between the Study and Control arms.
The combination of a hyperosmotic colon purgative
(NaP) and hyperosmotic diatrizoate solution for use
as a boost agent has previously been shown to be
[15]
effective . The study reported herein evaluated
the use of OSS as an alternative hyperosmotic colon
purgative. As a boost agent, OSS + diatrizoate
performed similarly to the combination of NaP and
diatrizoate solution with respect to colon cleansing
adequacy, CCE completion, overall GI transit time,
and polyp detection. While these results support OSS
as a boost agent in place of NaP, use of a historical
comparator is a limitation.
[1]
A large prospective CCE study by Rex et al found
an unexpectedly high number of capsule studies
(approximately 10%) could not be evaluated due to a
combination of inadequate preparation and rapid (< 40
min) colonic transit. A similar frequency (approximately
9%) of CCE studies with both inadequate cleansing
and colon transit < 40 min was observed with the

DISCUSSION
A new CCE preparation regimen using OSS +
diatrizoate as a boost agent did not improve colon
cleansing as compared to low dose OSS alone. The
OSS + diatrizoate regimen resulted in more rapid
transit of the capsule with a trend toward faster transit
through the entire GI tract, superior CCE completion,
and more frequent colonic transit less than 40 min.
There was also a trend toward higher polyp detection
with OSS + diatrizoate. More subjects receiving OSS
+ diatrizoate experienced adverse events which were
primarily related to the bowel regimen and GI in
nature, but did not appear to be related to diatrizoate
solution. Patient related factors, not identified in this
study, may have accounted for this difference in
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Study regimen. It is unknown whether this trend would
have continued had enrollment not been terminated
[1]
early. Our Control regimen differed from Rex et al
st
only in the OSS dose for the 1 boost [Control =
[1]
89 ml (3 oz.), Rex et al = 177 ml [6 oz.)]. As
[1]
compared to Rex et al boosts comprised of low dose
OSS alone did slow transit but at a cost of inferior CCE
completion. These data suggest that while CCE transit
[1]
is too often fast with the Rex et al . regimen, transit
st
nd
may be too slow when the 1 and 2 boost utilize low
[1]
dose OSS alone . Again, these conclusions are limited
by the use of a historical comparator.
Like colonoscopy, CCE’s effectiveness depends on
a complete colon exam and adequate preparation.
Achieving these endpoints with colon capsule is a
complicated endeavor in that the preparation regimen
must both cleanse the colon and propel the capsule.
The lumen must be fluid filled and clear of debris,
and the capsule needs to traverse the entire colon
within the limits of its battery life - but not too quickly
such that findings could be missed. And, just like
colonoscopy, complete passage through the colon
and adequate preparation are basic requirements and
no guarantee that lesions will not be missed. Using
colonoscopy as the gold standard, a meta-analysis
showed that the second-generation colon capsule
utilized in our study had high sensitivity and specificity
[18]
for polyps ≥ 6 mm . The acceptable standards for
CCE completion and adequate bowel preparation
remain to be determined, but it is reasonable to
believe that higher thresholds will translate into better
outcomes.
Our study has some additional limitations. While
enrollment was terminated early using pre-specified
criteria, outcomes may have varied if full enrollment
was achieved. While the difference between the Study
and Control regimens for polyp detection seen after
the first interim analysis at 50 subjects persisted
after enrollment closed, this was not the case for
preparation adequacy or adverse event incidence.
Colon cleansing was graded per segment and overall
(primary endpoint), but a preparation receiving an
overall grade of adequate could have one or more
individual segments graded as graded as fair or
poor. Looking to colonoscopy and the Boston Bowel
Preparation Scale for guidance, a total colon score of
> 5 is associated with both superior polyp detection
and high adherence to guidelines for screening and
[19]
surveillance . Yet, individual colon segment scores
are important, and segments scored < 2 are at greater
[20]
risk for missing polyps . For colon capsule, whether
an overall cleansing grade of adequate is sufficient
for quality measures such as polyp detection and
compliance with interval performance of this procedure
remains to be determined. Finally, in the study we
have presented, polyp detection by CCE was not
confirmed with colonoscopy. However, a meta-analysis
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demonstrating high sensitivity and specificity for
polyps ≥ 6 mm and ≥ 10 mm with the colon capsule
utilized for this study provides reassurance regarding
[18]
its accuracy for polyp detection .
In summary, a CCE preparation regimen combining
two hyperosmotic agents, OSS and diatrizoate
solution, as a boost agent was not superior to low
dose OSS alone for achieving adequate overall
colon cleansing. The OSS + diatrizoate regimen did
achieve a high rate of colon capsule completion, was
associated with trend toward higher polyp detection,
and performed similarly to a historic comparator boost
regimen comprised NaP + diatrizoate. The combination
of inadequate preparation and rapid colonic transit
seen in some subjects receiving OSS + diatrizoate,
which may lower the accuracy of CCE, is a potential
limitation of this regimen and requires additional
investigation. Future research efforts should continue
to focus on improving cleansing efficacy and patient
tolerance while maintaining high rates of colon capsule
completion. While permitting sufficient capsule dwell
time in the colon is important to minimize the risk for
missing lesions, the effect of rapid colonic transit may
be mitigated with adequate cleansing.

ARTICLEHIGHLIGHTS
HIGHLIGHTS
ARTICLE
Research background

The technical performance of colon capsule endoscopy (CCE) has made
great strides, but this technology remains highly dependent on the purgative
procedure. The ideal capsule preparation would (1) adequately cleanse the
colon; (2) propel the capsule through the GI tract within its battery life; (3)
enable sufficient dwell time within the colon for accurate visualization; (4) be
tolerable and safe; (5) be easily generalizable for the vast majority of patients.
Each of these areas require improvement, and this study’s significance is that it
moves this field forward by evaluating a new boost agent.

Research motivation

Tailoring the preparation procedure based on patient characteristics and realtime capsule feedback (“personalized” medicine) will likely improve CCE
performance, tolerability, safety, and subsequently acceptance. Technological
advancements that reliably visualize mucosa obscured by debris, and assist in
the detection of polyps, would be immensely helpful as well.

Research objectives

The main objective was to evaluate the efficacy of new boost agent consisting
of low dose sulfate solution combined with diatrizoate solution (“Study”
regimen), and comparing this to low dose sulfate solution alone (“Control”
regimen). We found that colon cleansing was similar between the two regimens,
but CCE completion and the proportion of subjects in which the capsule passed
through the colon in less than 40 min were significantly greater with the Study
regimen. Also observed was numerically greater, not statistically superior,
polyp detection with the Study regimen. This suggests that it is reasonable
to incorporate the boost regimen of low dose sulfate solution and diatrizoate
solution into the preparation procedure for CCE.

Research methods

This was a multicenter, prospective, randomized, controlled study comparing
two preparation regimens for CCE at six United States sites, 2 of which were
academic centers. CCE studies were read centrally by experienced readers
who were blinded to subject randomization, and a validated cleansing scale for
CCE was utilized.
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Research results

6

The study regimen did not result in superior colon cleansing, but did result in a
superior rate of CCE completion and higher proportion of studies with colonic
transit less than 40 min. Increased polyp detection, though not significant,
was observed in the Study arm suggesting that polyp detection was not
compromised in this group. However, this study was not powered for polyp
detection. We also observed a greater incidence of adverse events, primarily
GI, in the Study group. This observation in the Study group did not appear to
be related to the boost agent. Progress needs to be made in further improving
the efficacy of colon cleansing, with the goal for CCE being more closely
aligned with that established for traditional colonoscopy. Further, simplifying
the regimen, shortening overall GI transit time, and lessening the incidence
of adverse events related to the preparation regimen are all worthy of further
study.

7

8

Research conclusions

Diatrizoate solution augments the performance of sulfate solution to create
an effective and very low dose hyperosmotic boost agent for CCE. The
combination of low dose sulfate solution and diatrizoate solution was superior
to low dose sulfate solution alone with respect to CCE completion and the
frequency that the capsule traversed the colon in less than 40 minutes. These
findings, along with a trend toward higher polyp detection with the combination
Study regimen, support the use of low dose sulfate solution combined with
diatrizoate solution as a boost agent in place of low dose sulfate solution alone.

9

10

Research perspectives

While our findings represent an improvement in the preparation regimen for
CCE, there is still much progress to be made in this arena. In particular, the
rate of preparation adequacy needs to increase. Personalized medicine may
play a role in optimizing the regimen for CCE. Using patient characteristics and
real time capsule data, individual adjustments might include varying the volume
of PEG-ELS, utilizing additional agents, adjusting the frequency and timing of
medication administration, and more.

11
12
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